WHO WE ARE
We are Ipsen in rare disease. We are ordinary people with the extraordinary ambition to improve the health and prolong the lives of people living with rare diseases.
At Ipsen, we are dedicated to developing new and transformative treatment options for people living with rare diseases. We use our scientific expertise to develop medicine that have life changing potential for people living with a rare disease, because we believe in being there for those who often get left behind.
We are Ipsen in Rare Disease
We focus our research and innovation in the areas of greatest unmet need and where we can make a meaningful impact for patients. Our priority is advancing medicines and scientific understanding in rare liver disease, rare bone disease and endocrine growth disorders.
Ipsen’s unwavering commitment to patients
People living with a rare disease face daily barriers, including delayed diagnoses and delayed or inadequate treatment. The chronic, progressive, degenerative, and frequently life shortening nature of many rare diseases can have a profound impact on quality of life. We’re committed to supporting patients from diagnosis to treatment and partnering with the community to deliver better outcomes for everyone.
Learn more
Our focus on science
One of the biggest challenges in rare disease is the limited scientific research and knowledge available to inform our understanding. We initiate clinical development programs that advance scientific understanding of rare diseases and their impact, to pave the way for better disease management and future therapeutic advances.
Clinical trials
Our focus on innovation
Our mission is to bridge the gap between innovative science and improved outcomes for patients. We are focused on new treatment options that address what matters to doctors and patients and are investing our time and resources into investigating medicines that work differently, that have the life-changing potential to alter or slow the course of a disease and provide relief from the pain and distress of debilitating symptoms.
Our pipeline
